Irina Dyagil

TL;DR: This ongoing trial did not meet its primary end point of CCyR at 12 months, despite the observed higher MMR rate at 12 years, faster times to CCyr and MMR, fewer on-treatment transformations to accelerated/blast phase, and fewer CML-related deaths with bosutinib compared with imatinib.

TL;DR: Patients who received bosutinib had significantly higher rates of MMR and CCyR and achieved responses faster than those who received imatinib, indicating bosut inib may be an effective first-line treatment for chronic-phase CML.

TL;DR: Exposure to low doses and to low dose-rates of radiation from post-Chornobyl cleanup work was associated with a significant increase in risk of leukemia, which was statistically consistent with estimates for the Japanese atomic bomb survivors.

TL;DR: A nested case-control study of leukemia in a cohort of cleanup workers identified from the Chornobyl State Registry of Ukraine, based on 71 cases of histologically confirmed leukemia diagnosed in 1986–2000 and 501 age- and residence-matched controls selected from the same cohort, finds a similar dose–response relationship for chronic and non-chronic lymphocytic leukemia.

TL;DR: The design, procedures, outcome of case finding and confirmation, control selection, dose estimation and interviewing of subjects are described, and a new time-and-motion method known as RADRUE described in companion paper II.